Quanterix expands laboratory-developed-test menu with launch of neurofilament light chain test

Amyloid Plaque Alzheimer2 Social

Quanterix on Monday announced the validation of a laboratory developed test (LDT) to quantitatively measure neurofilament light chain (NfL) in serum as an aid in the evaluation of individuals for possible neurodegenerative conditions or other causes of neuronal or central nervous system damage.

NfL is a well-studied biomarker for neuroaxonal injury with wide applicability to different neurological disorders, the firm noted, adding that measurement of the protein in serum and plasma was first enabled with the release of its research-use-only (RUO) Simoa NfL kit several years ago.

“Assessment and monitoring of brain health is incredibly difficult and typically performed in limited fashion by surgery or imaging,” Masoud Toloue, CEO of Quanterix, said in a statement. “We see NfL as not only an important marker for neurodegenerative disease but also a critical measure of brain-related side effects during chemotherapy, CAR T-cell therapy, and stroke.”

The company expects the launch of its CLIA-validated NfL blood test will enable future therapeutic trials and advance clinical care, he added.

Page 1 of 3
Next Page